OncoMatch/Clinical Trials/NCT06844383
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Is NCT06844383 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Talazoparib with enzalutamide and Talazoparib for prostate cancer (adenocarcinoma).
Treatment: Talazoparib with enzalutamide · Talazoparib — The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate or darolutamide
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Cancer type
Prostate Cancer
Biomarker criteria
Required: ATM pathogenic mutation
Required: ATR pathogenic mutation
Required: BRCA1 pathogenic mutation
Required: BRCA2 pathogenic mutation
Required: CDK12 pathogenic mutation
Required: CHEK2 pathogenic mutation
Required: FANCA pathogenic mutation
Required: MLH1 pathogenic mutation
Required: MRE11A pathogenic mutation
Required: NBN pathogenic mutation
Required: PALB2 pathogenic mutation
Required: RAD51C pathogenic mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: abiraterone acetate or darolutamide (abiraterone acetate, darolutamide) — mHSPC, locally advanced disease, or non-metastatic castration-resistant disease
Progressed ... while receiving either abiraterone acetate with prednisone for mHSPC or locally advanced disease, OR darolutamide for mHSPC, locally advanced disease, or non-metastatic castration-resistant disease
Cannot have received: androgen receptor pathway inhibitor for metastatic CRPC
Exception: less than 12 weeks
Prior treatment for metastatic CRPC with an ARPI for ≥ 12 weeks
Cannot have received: abiraterone acetate with prednisone, enzalutamide, or apalutamide for non-metastatic CRPC (abiraterone acetate, enzalutamide, apalutamide)
Exception: less than 12 weeks
Prior treatment for non-metastatic CRPC with abiraterone acetate with prednisone, enzalutamide, or apalutamide for ≥ 12 weeks
Cannot have received: PARP inhibitor
Prior treatment with a PARP inhibitor
Cannot have received: platinum-based chemotherapy for prostate cancer
Prior platinum-based chemotherapy for the treatment of prostate cancer
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/µl; Hemoglobin ≥ 9g/dl; Platelet count ≥ 100,000/µl
Kidney function
Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN); Potassium ≥ 3.5 mmol/L (within institutional normal range)
Liver function
Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
Normal organ function with acceptable initial laboratory values within 35 days of treatment start: Absolute neutrophil count ≥ 1,500/µl; Hemoglobin ≥ 9g/dl; Platelet count ≥ 100,000/µl; Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN); Potassium ≥ 3.5 mmol/L (within institutional normal range); Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UCSD Moores Cancer Center · La Jolla, California
- Dana Farber Cancer Institute · Boston, Massachusetts
- Masonic Cancer Center · Minneapolis, Minnesota
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06844383 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen receptor pathway inhibitor for metastatic CRPC, abiraterone acetate with prednisone, enzalutamide, or apalutamide for non-metastatic CRPC, PARP inhibitor disqualifies patients from enrollment.
Does this trial require ATM?
Yes, ATM pathogenic mutation is a required biomarker for enrollment.
Does this trial require ATR?
Yes, ATR pathogenic mutation is a required biomarker for enrollment.
Does this trial require BRCA1?
Yes, BRCA1 pathogenic mutation is a required biomarker for enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify